- Advertisement -spot_img
Wednesday, September 28, 2022

Final agreement reached with Moderna to produce mRNA vaccines in Australia from 2024.

A definitive agreement has been signed between the federal government, the government of Victoria and vaccine manufacturer Moderna for the first production of mRNA vaccines in Australia.

Construction is expected to begin on a new plant in Victoria by the end of the year.

The plant will be able to produce up to 100 million doses of vaccine against COVID-19 and other diseases such as seasonal flu annually.

The announcement comes just months after an agreement in principle was signed between the parties last December.

Australia will be one of the few mRNA vaccine production sites worldwide, including the US and Europe, while Kenya has plans for a major new Moderna plant.

Moderna opened a subsidiary in Australia and recently announced significant expansion plans in the Asia-Pacific region.

Prime Minister Scott Morrison said it was critical that mRNA vaccines could be made on land.

“This will be the first mRNA facility in the Southern Hemisphere and will provide Australians with quick and easy access to these life-saving vaccines,” he said.

Targeting COVID, flu and more

It is hoped that the new plant will produce its first Australian-made vaccines sometime in 2024.

The exact location for the new plant will be decided between the Victorian government and Moderna.

Moderna said it has much more in mind than just COVID-19 vaccines and plans to develop a range of other respiratory drugs and vaccines.

One advantage of mRNA technology is that it can be relatively easily adapted to fight existing and emerging diseases.

Moderna’s general manager for Australia and New Zealand, Michael Azrak, said they look forward to working with Australian researchers to bring various vaccines and treatments to market.

“Moderna is supporting the development of a world-class mRNA industry in Australia,” he said.

“In addition to local manufacturing, we are going to collaborate with local researchers and institutions to conduct collaborative research and development that will enable the development of next-generation mRNA treatments.”

Two of the most likely early technology adaptations will target seasonal influenza and respiratory syncytial virus (RSV).

Space to play or pause, M to mute, left and right arrows to search, up and down arrows to volume.

Will winter bring the onslaught of COVID-19?

Loading form…

World Nation News Desk
World Nation News Deskhttps://worldnationnews.com/
World Nation News is a digital news portal website. Which provides important and latest breaking news updates to our audience in an effective and efficient ways, like world’s top stories, entertainment, sports, technology and much more news.
Latest news
Related news
- Advertisement -

LEAVE A REPLY

Please enter your comment!
Please enter your name here